114 related articles for article (PubMed ID: 25236537)
1. Dysregulation of the MIRLET7/HMGA2 axis with methylation of the CDKN2A promoter in myeloproliferative neoplasms.
Harada-Shirado K; Ikeda K; Ogawa K; Ohkawara H; Kimura H; Kai T; Noji H; Morishita S; Komatsu N; Takeishi Y
Br J Haematol; 2015 Feb; 168(3):338-49. PubMed ID: 25236537
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of HMGA2 by the pan-deacetylase inhibitor panobinostat is dependent on hsa-let-7b expression in liver cancer cell lines.
Di Fazio P; Montalbano R; Neureiter D; Alinger B; Schmidt A; Merkel AL; Quint K; Ocker M
Exp Cell Res; 2012 Sep; 318(15):1832-43. PubMed ID: 22683924
[TBL] [Abstract][Full Text] [Related]
3. The MYCN-HMGA2-CDKN2A pathway in non-small cell lung carcinoma--differences in histological subtypes.
Eide HA; Halvorsen AR; Bjaanæs MM; Piri H; Holm R; Solberg S; Jørgensen L; Brustugun OT; Kiserud CE; Helland Å
BMC Cancer; 2016 Feb; 16():71. PubMed ID: 26858029
[TBL] [Abstract][Full Text] [Related]
4. Aberrant let7a/HMGA2 signaling activity with unique clinical phenotype in
Chen CC; You JY; Lung J; Huang CE; Chen YY; Leu YW; Ho HY; Li CP; Lu CH; Lee KD; Hsu CC; Gau JP
Haematologica; 2017 Mar; 102(3):509-518. PubMed ID: 28057739
[TBL] [Abstract][Full Text] [Related]
5. [The role of HMGA2 in myeloproliferative neoplasms].
Ikeda K
Rinsho Ketsueki; 2018; 59(10):2067-2074. PubMed ID: 30305510
[TBL] [Abstract][Full Text] [Related]
6. Quantitative analysis of CDKN2A methylation, mRNA, and p16(INK4a) protein expression in children and adolescents with Burkitt lymphoma: biological and clinical implications.
Robaina MC; Faccion RS; Arruda VO; de Rezende LM; Vasconcelos GM; Apa AG; Bacchi CE; Klumb CE
Leuk Res; 2015 Feb; 39(2):248-56. PubMed ID: 25542698
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of apoptosis-related genes from death receptor pathway in chronic myeloproliferative diseases.
Tognon R; Gasparotto EP; Leroy JM; Oliveira GL; Neves RP; Carrara Rde C; Kashima S; Covas DT; Santana M; Souto EX; Zanichelli MA; Velano CE; Simões BP; Alberto FL; Miyashiro K; de Souza AM; Amarante-Mendes GP; de Castro FA
J Clin Pathol; 2011 Jan; 64(1):75-82. PubMed ID: 21045235
[TBL] [Abstract][Full Text] [Related]
8. 3'UTR-truncated Hmga2 cDNA causes MPN-like hematopoiesis by conferring a clonal growth advantage at the level of HSC in mice.
Ikeda K; Mason PJ; Bessler M
Blood; 2011 Jun; 117(22):5860-9. PubMed ID: 21460244
[TBL] [Abstract][Full Text] [Related]
9. The role of HMGA2 in the proliferation and expansion of a hematopoietic cell in myeloproliferative neoplasms.
Ikeda K; Ogawa K; Takeishi Y
Fukushima J Med Sci; 2012; 58(2):91-100. PubMed ID: 23237864
[TBL] [Abstract][Full Text] [Related]
10. MicroRNAs in myeloproliferative neoplasms.
Zhan H; Cardozo C; Raza A
Br J Haematol; 2013 May; 161(4):471-83. PubMed ID: 23432162
[TBL] [Abstract][Full Text] [Related]
11. Identification of a HMGA2-EFCAB6 gene rearrangement following next-generation sequencing in a patient with a t(12;22)(q14.3;q13.2) and JAK2V617F-positive myeloproliferative neoplasm.
Martin SE; Sausen M; Joseph A; Kingham BF; Martin ES
Cancer Genet; 2012 Jun; 205(6):295-303. PubMed ID: 22749035
[TBL] [Abstract][Full Text] [Related]
12. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene.
Lee YS; Dutta A
Genes Dev; 2007 May; 21(9):1025-30. PubMed ID: 17437991
[TBL] [Abstract][Full Text] [Related]
13. The Fragment HMGA2-sh-3p20 from HMGA2 mRNA 3'UTR Promotes the Growth of Hepatoma Cells by Upregulating HMGA2.
Wang Y; Chen F; Yang Z; Zhao M; Zhang S; Gao Y; Feng J; Yang G; Zhang W; Ye L; Zhang X
Sci Rep; 2017 May; 7(1):2070. PubMed ID: 28522832
[TBL] [Abstract][Full Text] [Related]
14. Promoter hypermethylation: a common cause of reduced p16(INK4a) expression in uveal melanoma.
van der Velden PA; Metzelaar-Blok JA; Bergman W; Monique H; Hurks H; Frants RR; Gruis NA; Jager MJ
Cancer Res; 2001 Jul; 61(13):5303-6. PubMed ID: 11431374
[TBL] [Abstract][Full Text] [Related]
15. Small RNA Sequencing Uncovers New miRNAs and moRNAs Differentially Expressed in Normal and Primary Myelofibrosis CD34+ Cells.
Guglielmelli P; Bisognin A; Saccoman C; Mannarelli C; Coppe A; Vannucchi AM; Bortoluzzi S
PLoS One; 2015; 10(10):e0140445. PubMed ID: 26468945
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of unmethylated CDKN2D by 5-aza-2'-deoxycytidine in human lung cancer cells.
Zhu WG; Dai Z; Ding H; Srinivasan K; Hall J; Duan W; Villalona-Calero MA; Plass C; Otterson GA
Oncogene; 2001 Nov; 20(53):7787-96. PubMed ID: 11753657
[TBL] [Abstract][Full Text] [Related]
17. Microarray and Proteomic Analyses of Myeloproliferative Neoplasms with a Highlight on the mTOR Signaling Pathway.
Čokić VP; Mossuz P; Han J; Socoro N; Beleslin-Čokić BB; Mitrović O; Subotički T; Diklić M; Leković D; Gotić M; Puri RK; Noguchi CT; Schechter AN
PLoS One; 2015; 10(8):e0135463. PubMed ID: 26275051
[TBL] [Abstract][Full Text] [Related]
18. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
[TBL] [Abstract][Full Text] [Related]
19. HMGA2 and the p19Arf-TP53-CDKN1A axis: a delicate balance in the growth of uterine leiomyomas.
Markowski DN; von Ahsen I; Nezhad MH; Wosniok W; Helmke BM; Bullerdiek J
Genes Chromosomes Cancer; 2010 Aug; 49(8):661-8. PubMed ID: 20544840
[TBL] [Abstract][Full Text] [Related]
20. miR-145, targeting high-mobility group A2, is a powerful predictor of patient outcome in ovarian carcinoma.
Kim TH; Song JY; Park H; Jeong JY; Kwon AY; Heo JH; Kang H; Kim G; An HJ
Cancer Lett; 2015 Jan; 356(2 Pt B):937-45. PubMed ID: 25444913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
